Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension
- 2 August 2011
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 89 (8) , 771-783
Abstract
Pulmonary arterial hypertension (PAH) is a vascular remodeling disease characterized by enhanced proliferation and suppressed apoptosis of pulmonary artery smooth muscle cells (PASMC). This apoptosis resistance is characterized by PASMC mitochondrial hyperpolarization [in part, due to decreased pyruvate dehydrogenase (PDH) activity], decreased mitochondrial reactive oxygen species (mROS), downregulation of Kv1.5, increased [Ca++]i, and activation of the transcription factor nuclear factor of activated T cells (NFAT). Inflammatory cells are present within and around the remodeled arteries and patients with PAH have elevated levels of inflammatory cytokines, including tumor necrosis factor-α (TNFα). We hypothesized that the inflammatory cytokine TNFα inhibits PASMC PDH activity, inducing a PAH phenotype in normal PASMC. We exposed normal human PASMC to recombinant human TNFα and measured PDH activity. In TNFα-treated cells, PDH activity was significantly decreased. Similar to exogenous TNFα, endogenous TNFα secreted from activated human CD8+ T cells, but not quiescent T cells, caused mitochondrial hyperpolarization, decreased mROS, decreased K+ current, increased [Ca++]i, and activated NFAT in normal human PASMC. A TNFα antibody completely prevented, while recombinant TNFα mimicked the T cell-induced effects. In vivo, the TNFα antagonist etanercept prevented and reversed monocrotaline (MCT)-induced PAH. In a separate model, T cell deficient rats developed less severe MCT-induced PAH compared to their controls. We show that TNFα can inhibit PASMC PDH activity and induce a PAH phenotype. Our work supports the use of anti-inflammatory therapies for PAH.Keywords
This publication has 36 references indexed in Scilit:
- Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial HypertensionCirculation, 2010
- Fatty Acid Oxidation and Malonyl-CoA Decarboxylase in the Vascular Remodeling of Pulmonary HypertensionScience Translational Medicine, 2010
- Metabolic Modulation of Glioblastoma with DichloroacetateScience Translational Medicine, 2010
- Lung Vascular Cell Heterogeneity: Endothelium, Smooth Muscle, and FibroblastsProceedings of the American Thoracic Society, 2008
- Pulmonary arterial remodeling induced by a Th2 immune responseJournal of Experimental Medicine, 2008
- The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targetedProceedings of the National Academy of Sciences, 2007
- Absence of T Cells Confers Increased Pulmonary Arterial Hypertension and Vascular RemodelingAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Alterations of cellular bioenergetics in pulmonary artery endothelial cellsProceedings of the National Academy of Sciences, 2007
- HIV-1 Nef Is Associated with Complex Pulmonary Vascular Lesions in SHIV- nef –infected MacaquesAmerican Journal of Respiratory and Critical Care Medicine, 2006
- An Abnormal Mitochondrial–Hypoxia Inducible Factor-1α–Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded RatsCirculation, 2006